Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

bioAffinity Technologies (BIAF) EBT (2022 - 2025)

Historic EBT for bioAffinity Technologies (BIAF) over the last 4 years, with Q3 2025 value amounting to -$5.0 million.

  • bioAffinity Technologies' EBT fell 15261.22% to -$5.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$14.7 million, marking a year-over-year decrease of 7431.28%. This contributed to the annual value of -$9.0 million for FY2024, which is 1404.95% down from last year.
  • Latest data reveals that bioAffinity Technologies reported EBT of -$5.0 million as of Q3 2025, which was down 15261.22% from -$4.0 million recorded in Q2 2025.
  • bioAffinity Technologies' 5-year EBT high stood at -$88052.0 for Q2 2022, and its period low was -$5.0 million during Q3 2025.
  • For the 4-year period, bioAffinity Technologies' EBT averaged around -$2.5 million, with its median value being -$2.1 million (2024).
  • The largest annual percentage gain for bioAffinity Technologies' EBT in the last 5 years was 5347.6% (2023), contrasted with its biggest fall of 187109.21% (2023).
  • Over the past 4 years, bioAffinity Technologies' EBT (Quarter) stood at -$1.7 million in 2022, then tumbled by 41.58% to -$2.4 million in 2023, then fell by 25.14% to -$3.0 million in 2024, then plummeted by 70.14% to -$5.0 million in 2025.
  • Its EBT stands at -$5.0 million for Q3 2025, versus -$4.0 million for Q2 2025 and -$2.7 million for Q1 2025.